New insider activity at Voyager Therapeutics ( (VYGR) ) has taken place on April 3, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Voyager Therapeutics has seen insider activity as President & CEO Alfred Sandrock sold 11,511 shares of the company’s stock in a recent transaction, generating proceeds totaling $44,547. This sale highlights notable trading by the company’s top executive and may draw attention from investors tracking insider movements at Voyager Therapeutics.
Recent Updates on VYGR stock
Voyager Therapeutics’ shares reacted to a strong Q4 revenue beat versus expectations, reinforcing confidence in its growth trajectory and cash runway projected into 2028. Management emphasized 2026 as a pivotal year with key Alzheimer’s data, clinical entry of IV gene therapies, and advancement of its NeuroShuttle platform, factors likely driving analysts to reassess long‑term prospects alongside newly disclosed tariff and China‑related supply chain risks that may pressure costs and timelines.
Spark’s Take on VYGR Stock
According to Spark, TipRanks’ AI Analyst, VYGR is a Neutral.
The score is held down primarily by weakened financial performance (large recent losses and rising cash burn) and a loss-making valuation profile (negative P/E). Technical indicators are broadly neutral with only modest positive momentum, while corporate events are mixed, balancing leadership-transition risk with upbeat pipeline progress messaging.
To see Spark’s full report on VYGR stock, click here.
More about Voyager Therapeutics
YTD Price Performance: 0.76%
Average Trading Volume: 717,632
Technical Sentiment Signal: Strong Sell
Current Market Cap: $236M